Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Elotuzumab, a recently approved antibody for the treatment of multiple myeloma, has been shown to stimulate Fcγ receptor (FcγR)-mediated antibody-dependent cellular cytotoxicity by natural killer (NK) cells toward myeloma cells. The modulatory effects of elotuzumab on other effector cells in the tumor microenvironment, however, has not been fully explored. Antibody-dependent cellular phagocytosis (ADCP) is a mechanism by which macrophages contribute to antitumor potency of monoclonal antibodies. Herein, we studied the NK cell independent effect of elotuzumab on tumor-associated macrophages using a xenograft tumor model deficient in NK and adaptive immune cells. We demonstrate significant antitumor efficacy of single-agent elotuzumab in immunocompromised xenograft models of multiple myeloma, which is in part mediated by Fc–FcγR interaction of elotuzumab with macrophages. Elotuzumab is shown in this study to induce phenotypic activation of macrophages in vivo and mediates ADCP of myeloma cells though a FcγR-dependent manner in vitro. Together, these findings propose a novel immune-mediated mechanism by which elotuzumab exerts anti-myeloma activity and helps to provide rationale for combination therapies that can enhance macrophage activity. Mol Cancer Ther; 17(7); 1454–63. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Determination of subcutaneous tumor size in athymic (nude) mice
Tomayko, M. M., & Reynolds, C. P. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00300234 · Cited by 1,830
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · cited 2×
“Elotuzumab is a novel IgG1 mAb that has recently been approved for the treatment of relapsed or refractory multiple myeloma in combination with lenalidomide and dexamethasone (6).”
BackgroundGeorgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Rajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
Characterization of murine macrophages from bone marrow, spleen and peritoneum
Wang, C., Yu, X., Cao, Q., Wang, Y., Zheng, G., Tan, T. K., Zhao, H., Zhao, Y., Wang, Y., & Harris, D. C. (2013) · BMC Immunology · doi:10.1186/1471-2172-14-6 · Cited by 225 · cited 10×
“Known to be increased in the presence of IFNg (40), PD-L1 expression was also upregulated upon treatment with elotuzumab.”
BackgroundInfluentialShi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402891 · Cited by 195
Cited by
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805762 · Cited by 535
Self-citationDimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02815 · Cited by 114
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00103-x · Cited by 48
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46
Metadata
- Authors
- Kurdi, A. T., Glavey, S. V., Bezman, N. A., Jhatakia, A., Guerriero, J. L., Manier, S., Moschetta, M., Mishima, Y., Roccaro, A., Detappe, A., Liu, C.-J., Sacco, A., Huynh, D., Tai, Y.-T., Robbins, M. D., Azzi, J., & Ghobrial, I. M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2018-07-01
- Volume
- 17
- Issue
- 7
- Pages
- 1454-1463
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2796970920
- Cited by
- 97
- References
- 9
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-0998
- The paper
- Kurdi, A. T., Glavey, S. V., Bezman, N. A., Jhatakia, A., Guerriero, J. L., Manier, S., Moschetta, M., Mishima, Y., Roccaro, A., Detappe, A., Liu, C.-J., Sacco, A., Huynh, D., Tai, Y.-T., Robbins, M. D., Azzi, J., & Ghobrial, I. M. (2018). Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0998
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.